Takeda Loses First Of Thousands Of U.S. Lawsuits Over Actos Drug
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical faces paying $6.5 million to a U.S. man to cover damages a court jury determined was caused by taking Actos (pioglitazone) to treat his diabetes.
You may also be interested in...
Gritstone Jumps Into COVID-19 Vaccine Race, Eyeing Mutant Strains
The company is developing a vaccine with both adenoviral and mRNA technology that could potentially overcome resistance mutations on the SARS-CoV-2 spike protein.
Philips Adds Capsule Technologies To Connected Care Business
Philips will pay $635m for the Massachusetts-based developer of a platform that connects medical devices and electronic medical records in hospitals.
Hand Sanitizer Problems Prompt US FDA Guidance On Keeping Methanol Out Of Other OTC Drugs
Final guidance, for pharmaceutical alcohol used as an active or inactive ingredient in other drugs as well as hand sanitizers, “will help pharmaceutical manufacturers avoid using pharmaceutical alcohol contaminated with or substituted with methanol in drug products.”
Need a specific report? 1000+ reports available
Buy Reports